Hepatitis C Virus Still Leading Cause of Hepatocellular Cancer in Men
THURSDAY, Sept. 7, 2023 -- The leading cause of hepatocellular carcinoma (HCC) is still hepatitis C virus (HCV) among men, but the rates of HCV-HCC have decreased since 2015, according to a study published online Sept. 5 in Clinical Gastroenterology... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 7, 2023 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news

Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma
FORT LEE, NEW JERSEY, July 17, 2023– Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. And a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 17, 2023 Category: Drugs & Pharmacology Source Type: news

AI plus CT improves cirrhosis prediction in liver disease patients
Adding artificial intelligence (AI) to CT imaging improves the prediction o...Read more on AuntMinnie.comRelated Reading: AI and CT facilitate opportunistic screening for enlarged spleen Photon-counting CT just as good as MRI for quantifying liver fat Multiparametric MRI features can predict liver cancer recurrence AI can identify hepatocellular carcinoma on liver CT exams CT, ultrasound provide chance for fatty liver disease screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 13, 2023 Category: Radiology Source Type: news

Serum FGL1 as Diagnostic Markers for HBV-Related HCC Serum FGL1 as Diagnostic Markers for HBV-Related HCC
Might serum fibrinogen-like protein be useful as a potential diagnostic marker in early stage HBV-related hepatocellular carcinoma?Laboratory Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 29, 2023 Category: Infectious Diseases Tags: Pathology & Lab Medicine Journal Article Source Type: news

Can AI Help Determine If Liver Cancer Will Respond to Standard Treatment?
(MedPage Today) -- VIENNA -- Researchers trained an artificial intelligence (AI) model to determine if a patient with hepatocellular carcinoma (HCC) will respond to standard treatment with atezolizumab (Tecentriq) plus bevacizumab (Avastin)... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 26, 2023 Category: Gastroenterology Source Type: news

Scientists Say They ’ve Reached Turning Point in Cancer Research With Vaccines
SEATTLE — The next big advance in cancer treatment could be a vaccine. After decades of limited success, scientists say research has reached a turning point, with many predicting more vaccines will be out in five years. These aren’t traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back. Targets for these experimental treatments include breast and lung cancer, with gains reported this year for deadly skin cancer melanoma and pancreatic cancer. More from TIME [video id=W5jcvwLu autostart="viewable"] “We’re getting something to work. Now we need to get...
Source: TIME: Health - June 26, 2023 Category: Consumer Health News Authors: Carla K. Johnson / AP Tags: Uncategorized Cancer wire Source Type: news

Scientists Say They ’ve Reached ‘Turning Point’ in Cancer Research With Vaccines
SEATTLE — The next big advance in cancer treatment could be a vaccine. After decades of limited success, scientists say research has reached a turning point, with many predicting more vaccines will be out in five years. These aren’t traditional vaccines that prevent disease, but shots to shrink tumors and stop cancer from coming back. Targets for these experimental treatments include breast and lung cancer, with gains reported this year for deadly skin cancer melanoma and pancreatic cancer. “We’re getting something to work. Now we need to get it to work better,” said Dr. James Gulley, who help...
Source: TIME: Health - June 26, 2023 Category: Consumer Health News Authors: Carla K. Johnson / AP Tags: Uncategorized Cancer wire Source Type: news

Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC):Developing new treatment options for people with blood cancersExtended follow-up data for Columvi ® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people...
Source: Roche Investor Update - May 26, 2023 Category: Pharmaceuticals Source Type: news

Elevar Therapeutics Submits New Drug Application to FDA for Combination of Rivoceranib and Camrelizumab as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma
Fort Lee, N.J., May 17, 2023 - Elevar Therapeutics, Inc., a wholly owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 17, 2023 Category: Drugs & Pharmacology Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blood cancer)EU approva...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
Basel, 26 April 2023As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blo...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news